Using technology to deliver therapy for children and young people is as effective as traditional face-to-face therapy, according to new research.
EyeBio targets registrational trial after early success of Wnt agonist in retinal diseases
EyeBio’s tri-specific Wnt agonist antibody improved visual and anatomical measures in a Phase Ib/IIa trial as a monotherapy and in combination with Regeneron’s Eylea, prompting